WuXi Biologics Achieves ISO 20400 Sustainable Procurement Certification, Strengthening Global Supply Chain Resilience

06 January 2026 | Tuesday | News

Internationally recognized certification underscores WuXi Biologics’ leadership in sustainable procurement, supplier lifecycle management, and net-zero value chain strategy, reinforcing its commitment to responsible growth across the pharmaceutical supply chainv

WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility across the supply chain. This recognition highlights WuXi Biologics' outstanding performance in sustainability and showcases the company's dedicated efforts in strengthening supply chain resilience.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "As a member and active participant of PSCI*, WuXi Biologics adheres to world-leading management strategies to build a robust supply chain that ultimately serves as the value chain empowering sustainable business growth. We deliver high-quality solutions to meet global client demands while making active contributions that spearhead responsible value chain advancement in the pharmaceutical industry."

Supplier Lifecycle Management

WuXi Biologics has embedded sustainability principles across its entire system of supplier lifecycle management — from supplier due diligence and admission, to risk management and engagement, to performance review and termination. This not only ensures that suppliers consistently meet quality, compliance, and sustainability standards throughout their partnerships, but also enables transparent and traceable supply chains, mitigates risks, improves operational efficiency, and drives responsible practices among suppliers.

Net-Zero Across Value Chain

Deeply understanding the importance of tackling climate change, WuXi Biologics has adopted an integrated strategy with measurable SBTi targets and refined roadmaps. While diligently pursuing its own climate goals, the company also actively engages with suppliers through comprehensive sustainable supply chain management to help achieve positive impacts across the entire value chain.

As a participant of the United Nations Global Compact (UNGC), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP "A List" for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

*PSCI: Pharmaceutical Supply Chain Initiative, the leading association for pharmaceutical and healthcare companies with a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close